Endovascular vs Medical Management for Late Anterior Large Vessel Occlusion With Prestroke Disability: Analysis of CLEAR and RESCUE-Japan.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
received:
10
03
2022
accepted:
26
09
2022
pubmed:
5
11
2022
medline:
16
2
2023
entrez:
4
11
2022
Statut:
ppublish
Résumé
Current guidelines do not address recommendations for mechanical thrombectomy (MT) in the extended time window (>6 hours after time last seen well [TLSW]) for large vessel occlusion (LVO) patients with preexisting modified Rankin Scale (mRS) > 1. In this study, we evaluated the outcomes of MT vs medical management in patients with prestroke disability presenting in the 6- to 24-hour time window with acute LVO. We analyzed a multinational cohort (61 sites, 6 countries from 2014 to 2020) of patients with prestroke (or baseline) mRS 2 to 4 and anterior circulation LVO treated 6-24 hours from TLSW. Patients treated in the extended time window with MT vs medical management were compared using multivariable logistic regression and inverse probability of treatment weighting (IPTW). The primary outcome was the return of Rankin (ROR, return to prestroke mRS by 90 days). Of 554 included patients (448 who underwent MT), the median age was 82 years (interquartile range [IQR] 72-87) and the National Institutes of Health Stroke Scale (NIHSS) was 18 (IQR 13-22). In both MV logistic regression and IPTW analysis, MT was associated with higher odds of ROR (adjusted OR [aOR] 3.96, 95% CI 1.78-8.79 and OR 3.10, 95% CI 1.20-7.98, respectively). Among other factors, premorbid mRS 4 was associated with higher odds of ROR (aOR, 3.68, 95% CI 1.97-6.87), while increasing NIHSS (aOR 0.90, 95% CI 0.86-0.94) and decreasing Alberta Stroke Program Early Computed Tomography Scale score (aOR per point 0.86, 95% CI 0.75-0.99) were associated with lower odds of ROR. Age, intravenous thrombolysis, and occlusion location were not associated with ROR. In patients with preexisting disability presenting in the 6- to 24-hour time window, MT is associated with a higher probability of returning to baseline function compared with medical management. This investigation's results provide Class III evidence that in patients with preexisting disability presenting 6-24 hours from the TLSW and acute anterior LVO stroke, there may be a benefit of MT over medical management in returning to baseline function.
Sections du résumé
BACKGROUND AND OBJECTIVES
Current guidelines do not address recommendations for mechanical thrombectomy (MT) in the extended time window (>6 hours after time last seen well [TLSW]) for large vessel occlusion (LVO) patients with preexisting modified Rankin Scale (mRS) > 1. In this study, we evaluated the outcomes of MT vs medical management in patients with prestroke disability presenting in the 6- to 24-hour time window with acute LVO.
METHODS
We analyzed a multinational cohort (61 sites, 6 countries from 2014 to 2020) of patients with prestroke (or baseline) mRS 2 to 4 and anterior circulation LVO treated 6-24 hours from TLSW. Patients treated in the extended time window with MT vs medical management were compared using multivariable logistic regression and inverse probability of treatment weighting (IPTW). The primary outcome was the return of Rankin (ROR, return to prestroke mRS by 90 days).
RESULTS
Of 554 included patients (448 who underwent MT), the median age was 82 years (interquartile range [IQR] 72-87) and the National Institutes of Health Stroke Scale (NIHSS) was 18 (IQR 13-22). In both MV logistic regression and IPTW analysis, MT was associated with higher odds of ROR (adjusted OR [aOR] 3.96, 95% CI 1.78-8.79 and OR 3.10, 95% CI 1.20-7.98, respectively). Among other factors, premorbid mRS 4 was associated with higher odds of ROR (aOR, 3.68, 95% CI 1.97-6.87), while increasing NIHSS (aOR 0.90, 95% CI 0.86-0.94) and decreasing Alberta Stroke Program Early Computed Tomography Scale score (aOR per point 0.86, 95% CI 0.75-0.99) were associated with lower odds of ROR. Age, intravenous thrombolysis, and occlusion location were not associated with ROR.
DISCUSSION
In patients with preexisting disability presenting in the 6- to 24-hour time window, MT is associated with a higher probability of returning to baseline function compared with medical management.
CLASSIFICATION OF EVIDENCE
This investigation's results provide Class III evidence that in patients with preexisting disability presenting 6-24 hours from the TLSW and acute anterior LVO stroke, there may be a benefit of MT over medical management in returning to baseline function.
Identifiants
pubmed: 36332983
pii: WNL.0000000000201543
doi: 10.1212/WNL.0000000000201543
pmc: PMC9969918
doi:
Substances chimiques
Fibrinolytic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e751-e763Subventions
Organisme : NINDS NIH HHS
ID : R01 NS121154
Pays : United States
Organisme : NIBIB NIH HHS
ID : U18 EB029353
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 American Academy of Neurology.
Références
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Neurology. 2012 Feb 7;78(6):427-32
pubmed: 22311929
Stroke. 2015 Aug;46(8):2238-43
pubmed: 26138130
N Engl J Med. 2021 Nov 11;385(20):1833-1844
pubmed: 34758251
Stroke. 2012 Dec;43(12):3184-8
pubmed: 23150650
J Neurol. 2020 Sep;267(9):2667-2674
pubmed: 32410019
J Stroke Cerebrovasc Dis. 2021 Jul;30(7):105848
pubmed: 33991770
Neurology. 2021 Nov 9;97(19):e1914-e1919
pubmed: 34544817
Circulation. 2018 May 22;137(21):e661-e689
pubmed: 29674324
J Neurointerv Surg. 2021 Oct;13(10):865-868
pubmed: 33127734
Int J Stroke. 2022 Aug;17(7):815-819
pubmed: 35102797
J Am Heart Assoc. 2021 Aug 3;10(15):e020783
pubmed: 34284599
J Am Heart Assoc. 2018 Apr 25;7(9):
pubmed: 29695384
JAMA. 2021 Jan 19;325(3):234-243
pubmed: 33464335
JAMA Neurol. 2022 Jan 1;79(1):22-31
pubmed: 34747975
N Engl J Med. 2020 May 21;382(21):1981-1993
pubmed: 32374959
Lancet. 2014 Nov 29;384(9958):1929-35
pubmed: 25106063
Stroke. 2020 May;51(5):1539-1545
pubmed: 32268851
Neurology. 2012 Jun 12;78(24):1916-22
pubmed: 22649218
Stroke. 2022 Dec;53(12):3594-3604
pubmed: 36252092
JAMA. 2021 Jan 19;325(3):244-253
pubmed: 33464334
Interv Neurol. 2018 Apr;7(5):246-255
pubmed: 29765394
Front Neurol. 2017 Jun 13;8:275
pubmed: 28659859
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
J Stroke Cerebrovasc Dis. 2018 Jan;27(1):92-96
pubmed: 28882658
Stroke. 2002 Apr;33(4):1041-7
pubmed: 11935058
Neurol Med Chir (Tokyo). 2021 Mar 15;61(3):163-192
pubmed: 33583863
J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2268-2272
pubmed: 31160220
Stroke. 2022 Sep;53(9):2988-2990
pubmed: 35876017
J Stroke Cerebrovasc Dis. 2022 Nov;31(11):106804
pubmed: 36206608
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
AJNR Am J Neuroradiol. 2019 Feb;40(2):283-286
pubmed: 30573460